GlassScriptPhysician profile
Howard D Ehrenfeld
NPI 1477647170
$5,781.72
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,634 · 2020: $799 · 2021: $239 · 2022: $110.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,599.32 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $552.78 | 2019-2020 | |
| Amgen INC. | $517.20 | 2019 | |
| Biogen, INC. | $509.58 | 2019-2020 | |
| Genzyme Corporation | $462.09 | 2019-2021 | |
| Novo Nordisk INC | $251.81 | 2019-2020 | |
| Amarin Pharma, INC. | $247.02 | 2019 | |
| Lilly USA, LLC | $233.03 | 2019 | |
| Shire North American Group INC | $227.70 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $153.34 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $135.69 | 2019 | |
| Celgene Corporation | $125.98 | 2019 | |
| Acorda Therapeutics, INC | $125.00 | 2019 | |
| Neurocrine Biosciences, INC. | $125.00 | 2020 | |
| Avanir Pharmaceuticals, INC. | $120.00 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adamas Pharmaceuticals, INC. | $119.05 | 2019 | |
| Ucb, INC. | $94.71 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $94.32 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $37.48 | 2020 | |
| Mannkind Corporation | $28.56 | 2019 | |
| Insulet Corporation | $22.06 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Ehrenfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.